Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed FCF Margin across 7 years of filings, most recently posting 12.89% for Q1 2026.

• FCF Margin for Q1 2026 came in at 12.89%, down 544.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 38.01% (up 829.0% YoY), and the FY2025 annual result was 40.06%, up 946.0% from the prior year.
• FCF Margin came in at 12.89% for Q1 2026 at Harmony Biosciences Holdings, down from 51.7% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 51.7% in Q4 2025 to a low of 12.89% in Q1 2026.
• The 5-year median for FCF Margin is 35.73% (2023), against an average of 33.45%.
• Across the five-year window, FCF Margin sank 2036 bps in 2022 and surged 2467 bps in 2023, its largest moves.
• Harmony Biosciences Holdings' FCF Margin stood at 20.79% in 2022, then jumped by 119 bps to 45.46% in 2023, then declined by 18 bps to 37.29% in 2024, then surged by 39 bps to 51.7% in 2025, then tumbled by 75 bps to 12.89% in 2026.
• The last three FCF Margin figures came in at 12.89% (Q1 2026), 51.7% (Q4 2025), and 45.38% (Q3 2025), per Business Quant data.